NS3 GT3
Download full data set for GT3
Asunaprevir
| Mutation | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (3a_S52) | 1162 | 1x | resistance likely | | 1, 2 | |
| K26R | | | | | | |
| L36W | | | | | | |
| Q41H | | | | | | |
| Q41K | | | | | | |
| Q41L | | | | | | |
| Q41R | | | | | | |
| F43L | | | | | | |
| F43S | | | | | | |
| F43Y | | | | | | |
| T47I | | | | | | |
| T54A | | | | | | |
| T54S | | | | | | |
| V55A | | | | | | |
| V55I | | | | | | |
| Y56H | | | | | | |
| Y56N | | | | | | |
| Q80R | | | | | | |
| Q80K | | | | | | |
| V107I | | | | | | |
| D110N | | | | | | |
| S122A | | | | | | |
| S122C | | | | | | |
| S122F | | | | | | |
| S122P | | | | | | |
| S122R | | | | | | |
| S122T | | | | | | |
| S122Y | | | | | | |
| L132V | | | | | | |
| L132I | | | | | | |
| C134R | | | | | | |
| R155C | | | | | | |
| R155K | | | | | | |
| R155G | | | | | | |
| R155M | | | | | | |
| R155T | | | | | | |
| R155W | | | | | | |
| A156G | | | | | | |
| A156P | | | | | | |
| A156S | | | | | | |
| A156T | | | | | | |
| A156V | | | | | | |
| V158I | | | | | | |
| S166A | | | | | | |
| A166T | | | | | | |
| A166S | | | | | | |
| A166Y | | | | | | |
| Q168A | | | | | | |
| Q168E | | | | | | |
| Q168F | | | | | | |
| Q168G | | | | | | |
| Q168H | | | | | | |
| Q168I | | | | | | |
| Q168K | | | | | | |
| Q168L | | | | | | |
| Q168N | | | | | | |
| Q168R | | | | | | |
| Q168T | | | | | | |
| Q168V | | | | | | |
| Q168Y | | | | | | |
| V170I | | | | | | |
| V170L | | | | | | |
| V170M | | | | | | |
| L175M | | | | | | |
| Q178R | | | | | | |
| D186L | | | | | | |
| D186R | | | | | | |
| A294V | | | | | | |
| I366V | | | | | | |
| K26R+Q168R | | | | | | |
| V36M+R155K | | | | | | |
| Q41R+A156T | | | | | | |
| Q41R+Q168R | | | | | | |
| Q41R+V170I | | | | | | |
| Q41R+V55I | | | | | | |
| Q41T+V170I | | | | | | |
| T54S+V170I | | | | | | |
| T54A+V55A | | | | | | |
| T54S+V55I | | | | | | |
| V55I+V170I | | | | | | |
| Y56H+A156G | | | | | | |
| Y56H+S166A | | | | | | |
| Y56H+S166T | | | | | | |
| Y56H+Q168K | | | | | | |
| Y56H+Q168L | | | | | | |
| Y56H+Q168R | | | | | | |
| Y56H+Q168A | | | | | | |
| Y56H+Q168V | | | | | | |
| Q80R+ A 166T | | | | | | |
| Q80R+V170I | | | | | | |
| C134R+A156T | | | | | | |
| R155K+A156T | | | | | | |
| S166A+Q168K | | | | | | |
| S166A+Q168L | | | | | | |
| S166A+Q168R | | | | | | |
| Q168H+A156V | | | | | | |
| Y56H+S155A+Q168K | | | | | | |
| Y56H+S155A+Q168L | | | | | | |
| Y56H+S155A+Q168R | | | | | | |
| 1. Kwo PY et al. EASL 2016 http://www.natap.org/2016/EASL/EASL_40.htm |
| 2. Sunvepra Canadian Prodcut Monograph 2016 |
Glecaprevir
| Mutation | EC50 (nM) | Fold-shift | Fold-shift range | Phenotype | Clinical RAS | Reference | Comments | SVR with RAV |
| WT (3a_S52) | 0.71 | 1x | 0.71-1.9 | likely susceptible | No | 1,2,6 | only 3x FC vs GT1; clinical isolate=0.3 (0.05-3.8) | 90-99% (4) |
| K26R | | | | | | | | |
| L36W | | | | | | | | |
| Q41H | | | | | | | | |
| Q41K | | | | | | | | |
| Q41L | | | | | | | | |
| Q41R | | | | | | | | |
| F43L | | | | | | | | |
| F43S | | | | | | | | |
| F43Y | | | | | | | | |
| T47I | | | | | | | | |
| T54A | | | | | | | | |
| T54S | | | | resistance possible | Yes | 6 | Clinical VF RAV (6) | |
| V55A | | | | | | | | |
| V55I | | | | | | | | |
| Y56H | | | | resistance possible | Yes | 4,5,6,3 | Clinical TE RAV (4,5,6,3) | |
| Y56N | | | | resistance possible | Yes | 4,6 | Clinical TE RAV (4,6) | |
| Q80R | 11.5 | 21x | | resistance likely | Yes | 6,4 | Clinical TE RAV (4,6) | |
| Q80K | | 21x | | resistance likely | Yes | 4,6 | Clinical TE RAV (4,6) | |
| V107I | | | | resistance possible | Yes | 6 | Clinical VF RAV (6) | |
| D110N | | | | | | | | |
| S122A | | | | | | | | |
| S122C | | | | | | | | |
| S122F | | | | | | | | |
| S122P | | | | | | | | |
| S122R | | | | | | | | |
| S122T | | | | | | | | |
| S122Y | | | | | | | | |
| L132V | | | | | | | | |
| L132I | | | | resistance possible | Yes | 6 | Clinical VF RAV (6) | |
| C134R | | | | | | | | |
| R155C | | | | | | | | |
| R155K | 0.28 | 0.5x | | likely susceptible | | 6 | | |
| R155G | | | | | | | | |
| R155M | | | | | | | | |
| R155T | | | | | | | | |
| R155W | | | | | | | | |
| A156G | 1100 | 1500x | | resistance likely | Yes | 2,4,6 | Clinical TE RAV (4,6) | |
| A156P | | | | | | | | |
| A156S | | | | | | | | |
| A156T | | | | | | | | |
| A156V | | | | | | | | |
| V158I | | | | | | | | |
| S166A | unfit | | | | | 6 | | |
| A166T | 2.6 | 4.7x | | resistance likely | Yes | 4,5,3,6 | Clinical VF RAV (4,5,3). FC (S166T) | |
| A166S | | | | resistance possible | Yes | 4,5,6 | Clinical VF RAV (4,5,6) | |
| A166Y | | | | resistance possible | Yes | 6 | Clinical TE RAS (6) | |
| Q168A | | | | | | | | |
| Q168E | | | | | | | | |
| Q168F | | | | | | | | |
| Q168G | | | | | | | | |
| Q168H | 0.4 | 0.7x | | likely susceptible | | 6 | | |
| Q168I | | | | | | | | |
| Q168K | unfit | | | resistance possible | Yes | 5,3,6 | Clinical TE RAV (5,3) | |
| Q168L | 6.9 | 13x | | resistance likely | Yes | 4,6 | Clinical TE RAV (4,6) | |
| Q168N | | | | | | | | |
| Q168R | 30 | 54x | | resistance likely | Yes | 4,5,6,3 | Clinical TE RAV (4,5,6,3) | 50% (4) |
| Q168T | | | | | | | | |
| Q168V | | | | | | | | |
| Q168Y | | | | | | | | |
| V170I | | | | | | | | |
| V170L | | | | | | | | |
| V170M | | | | | | | | |
| L175M | | | | | | | | |
| Q178R | | | | | | | | |
| D186L | | | | resistance possible | Yes | 6 | Clinical TE RAS (6) | |
| D186R | | | | resistance possible | Yes | 6 | Clinical TE RAS (6) | |
| A294V | | | | | | | | |
| I366V | | | | resistance possible | Yes | 6 | Clinical TE RAS (6) | |
| K26R+Q168R | | | | | | | | |
| V36M+R155K | | | | | | | | |
| Q41R+A156T | | | | | | | | |
| Q41R+Q168R | | | | | | | | |
| Q41R+V170I | | | | | | | | |
| Q41R+V55I | | | | | | | | |
| Q41T+V170I | | | | | | | | |
| T54S+V170I | | | | | | | | |
| T54A+V55A | | | | | | | | |
| T54S+V55I | | | | | | | | |
| V55I+V170I | | | | | | | | |
| Y56H+A156G | unfit | | | | | 6 | | |
| Y56H+S166A | unfit | | | | | 6 | | |
| Y56H+S166T | unfit | | | | | 6 | | |
| Y56H+Q168K | unfit | | | | | 6 | | |
| Y56H+Q168L | unfit | | | | | 6 | | |
| Y56H+Q168R | 760 | 1100-1387x | | resistance likely | Yes | 2,4,6 | Clinical VF RAV (3) | |
| Y56H+Q168A | | | | | | | | |
| Y56H+Q168V | | | | | | | | |
| Q80R+ A 166T | 29.8 | 54x | | resistance likely | | 6 | | |
| Q80R+V170I | | | | | | | | |
| C134R+A156T | | | | | | | | |
| R155K+A156T | | | | | | | | |
| S166A+Q168K | unfit | | | | | | | |
| S166A+Q168L | unfit | | | | | | | |
| S166A+Q168R | unfit | | | | | | | |
| Q168H+A156V | | | | | | | | |
| Y56H+S155A+Q168K | unfit | | | | | | | |
| Y56H+S155A+Q168L | unfit | | | | | | | |
| Y56H+S155A+Q168R | unfit | | | | | | | |
| 1. Kwo PY et al. EASL 2016 http://www.natap.org/2016/EASL/EASL_40.htm |
| 2. Ng et al. [Abstract 636]. -CROI. Boston, 2014 http://www.croiconference.org/sites/all/abstracts/636.pdf |
| 3 Ng et al. EASL 2016. Abstract THU-240. http://www.natap.org/2016/EASL/EASL_123.htm |
| 4. Krishnan P, et al. 2017. Journal of Hepatology 66: S500. http://natap.org/2017/EASL/EASL_18.htm |
| 5. Kwo PY, et al. 2017. Journal of Hepatology 67: 263-71 |
| 6. FDA Microbiology Review https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394Orig1s000MicroR.pdf |
Grazoprevir
| Mutation | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (3a_S52) | 5.85 | 1x | likely susceptible | | 1 | Q168Q is 20x vs. Gt1a, exceed projected clinical exposure, |
| K26R | | | | | | |
| L36W | | | | | | |
| Q41H | | | | | | |
| Q41K | | | | | | |
| Q41L | | | | | | |
| Q41R | | 2.1x | likely susceptible | | 2 | |
| F43L | | | | | | |
| F43S | | | | | | |
| F43Y | | | | | | |
| T47I | | 1.4x | likely susceptible | | 2 | |
| T54A | | | | | | |
| T54S | | | | | | |
| V55A | | | | | | |
| V55I | | | | | | |
| Y56H | 41 | 7x | resistance possible | | 1 | |
| Y56N | | | | | | |
| Q80R | | | | | | |
| Q80K | | | | | | |
| V107I | | | | | | |
| D110N | | 1.1x | likely susceptible | | 2 | |
| S122A | | | | | | |
| S122C | | | | | | |
| S122F | | | | | | |
| S122P | | | | | | |
| S122R | | | | | | |
| S122T | | | | | | |
| S122Y | | | | | | |
| L132V | | | | | | |
| L132I | | | | | | |
| C134R | | 1.1x | likely susceptible | | 2 | |
| R155C | | | | | | |
| R155K | | 0.4x | likely susceptible | | 2 | |
| R155G | | | | | | |
| R155M | | | | | | |
| R155T | | | | | | |
| R155W | | | | | | |
| A156G | | | | | | |
| A156P | | | | | | |
| A156S | | | | | | |
| A156T | | 16x | resistance likely | | 2 | |
| A156V | | 22x | resistance likely | | 2 | |
| V158I | | | | | | |
| S166A | | | | | | |
| A166T | | | | | | |
| A166S | | 1.2x | likely susceptible | | 2 | |
| A166Y | | | | | | |
| Q168A | | | | | | |
| Q168E | | | | | | |
| Q168F | | | | | | |
| Q168G | | | | | | |
| Q168H | | 0.6x | likely susceptible | | | |
| Q168I | | | | | | |
| Q168K | | | | | | |
| Q168L | | | | | | |
| Q168N | | | | | | |
| Q168R | 23.4 | 4x | likely susceptible | | 1,3 | |
| Q168T | | | | | | |
| Q168V | | | | | | |
| Q168Y | | | | | | |
| V170I | | | | | | |
| V170L | | | | | | |
| V170M | | | | | | |
| L175M | | | | | | |
| Q178R | 29.3 | 5x | resistance possible | | 1 | |
| D186L | | | | | | |
| D186R | | | | | | |
| A294V | | | | | | |
| I366V | | | | | | |
| K26R+Q168R | | | | | | |
| V36M+R155K | | | | | | |
| Q41R+A156T | | 22x | resistance likely | | 2 | |
| Q41R+Q168R | | 15x | resistance likely | | 2 | |
| Q41R+V170I | | | | | | |
| Q41R+V55I | | | | | | |
| Q41T+V170I | | | | | | |
| T54S+V170I | | | | | | |
| T54A+V55A | | | | | | |
| T54S+V55I | | | | | | |
| V55I+V170I | | | | | | |
| Y56H+A156G | | | | | | |
| Y56H+S166A | | | | | | |
| Y56H+S166T | | | | | | |
| Y56H+Q168K | | | | | | |
| Y56H+Q168L | | | | | | |
| Y56H+Q168R | | | | | | |
| Y56H+Q168A | | | | | | |
| Y56H+Q168V | | | | | | |
| Q80R+ A 166T | | | | | | |
| Q80R+V170I | | | | | | |
| C134R+A156T | | 16x | resistance likely | | 2 | |
| R155K+A156T | | 11x | resistance likely | | 2 | |
| S166A+Q168K | | | | | | |
| S166A+Q168L | | | | | | |
| S166A+Q168R | | | | | | |
| Q168H+A156V | | 50x | resistance likely | | 2 | |
| Y56H+S155A+Q168K | | | | | | |
| Y56H+S155A+Q168L | | | | | | |
| Y56H+S155A+Q168R | | | | | | |
| 1. Zapatier Product Label (Canada) |
| 2. FDA Vosevi Microbiology Reviews 209195Orig1s000MicroR |
| 3. Foster et al. 2017 PMID: 29473975 DOI: 10.1002/hep.29852 |
Paritaprevir
| Mutation | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (3a_S52) | 19 | 1x | resistance likely | | 1 | EC50 above Cmin. L36, S166=RAS |
| K26R | | | | | | |
| L36W | | | | | | |
| Q41H | | | | | | |
| Q41K | | | | | | |
| Q41L | | | | | | |
| Q41R | | | | | | |
| F43L | | | | | | |
| F43S | | | | | | |
| F43Y | | | | | | |
| T47I | | | | | | |
| T54A | | | | | | |
| T54S | | | | | | |
| V55A | | | | | | |
| V55I | | | | | | |
| Y56H | 0.12 | 8x | resistance possible | | | |
| Y56N | | | | | | |
| Q80R | | | | | | |
| Q80K | | | | | | |
| V107I | | | | | | |
| D110N | | | | | | |
| S122A | | | | | | |
| S122C | | | | | | |
| S122F | | | | | | |
| S122P | | | | | | |
| S122R | | | | | | |
| S122T | | | | | | |
| S122Y | | | | | | |
| L132V | | | | | | |
| L132I | | | | | | |
| C134R | | | | | | |
| R155C | | | | | | |
| R155K | | | | | | |
| R155G | | | | | | |
| R155M | | | | | | |
| R155T | | | | | | |
| R155W | | | | | | |
| A156G | | | | | | |
| A156P | | | | | | |
| A156S | | | | | | |
| A156T | | | | | | |
| A156V | | | | | | |
| V158I | | | | | | |
| S166A | | | | | | |
| A166T | | | | | | |
| A166S | | | | | | |
| A166Y | | | | | | |
| Q168A | | | | | | |
| Q168E | | | | | | |
| Q168F | | | | | | |
| Q168G | | | | | | |
| Q168H | | | | | | |
| Q168I | | | | | | |
| Q168K | | | | | | |
| Q168L | | | | | | |
| Q168N | | | | | | |
| Q168R | | | | | | |
| Q168T | | | | | | |
| Q168V | 15 | 313x | resistance likely | | | |
| Q168Y | | | | | | |
| V170I | | | | | | |
| V170L | | | | | | |
| V170M | | | | | | |
| L175M | | | | | | |
| Q178R | | | | | | |
| D186L | | | | | | |
| D186R | | | | | | |
| A294V | | | | | | |
| I366V | | | | | | |
| K26R+Q168R | | | | | | |
| V36M+R155K | | | | | | |
| Q41R+A156T | | | | | | |
| Q41R+Q168R | | | | | | |
| Q41R+V170I | | | | | | |
| Q41R+V55I | | | | | | |
| Q41T+V170I | | | | | | |
| T54S+V170I | | | | | | |
| T54A+V55A | | | | | | |
| T54S+V55I | | | | | | |
| V55I+V170I | | | | | | |
| Y56H+A156G | | | | | | |
| Y56H+S166A | | | | | | |
| Y56H+S166T | | | | | | |
| Y56H+Q168K | | | | | | |
| Y56H+Q168L | | | | | | |
| Y56H+Q168R | | | | | | |
| Y56H+Q168A | | | | | | |
| Y56H+Q168V | 188 | 12,533x | resistance likely | | | |
| Q80R+ A 166T | | | | | | |
| Q80R+V170I | | | | | | |
| C134R+A156T | | | | | | |
| R155K+A156T | | | | | | |
| S166A+Q168K | | | | | | |
| S166A+Q168L | | | | | | |
| S166A+Q168R | | | | | | |
| Q168H+A156V | | | | | | |
| Y56H+S155A+Q168K | | | | | | |
| Y56H+S155A+Q168L | | | | | | |
| Y56H+S155A+Q168R | | | | | | |
| 1. Viekira Pak US Product Label jan 28, 2016 |
| 2. Krishnan et al., (2015) AAC 59:979-987 |
Simeprevir
| Mutation | EC50 (nM) | Fold-shift | Fold Shift Range | Phenotype | Clinical RAS | Reference | Comments |
| WT (3a_S52) | | 1x | | likely susceptible | | 1 | |
| K26R | | | | | | | |
| L36W | | | | | | | |
| Q41H | | | | | | | |
| Q41K | | | | | | | |
| Q41L | | | | | | | |
| Q41R | | | | | | | |
| F43L | | | | | | | |
| F43S | | | | | | | |
| F43Y | | | | | | | |
| T47I | | | | | | | |
| T54A | | | | | | | |
| T54S | | | | | | | |
| V55A | | | | | | | |
| V55I | | | | | | | |
| Y56H | | | | | | | |
| Y56N | | | | | | | |
| Q80R | | | | | | | |
| Q80K | | | | | | | |
| V107I | | | | | | | |
| D110N | | | | | | | |
| S122A | | | | | | | |
| S122C | | | | | | | |
| S122F | | | | | | | |
| S122P | | | | | | | |
| S122R | | | | | | | |
| S122T | | | | | | | |
| S122Y | | | | | | | |
| L132V | | | | | | | |
| L132I | | | | | | | |
| C134R | | | | | | | |
| R155C | | | | | | | |
| R155K | | 2x | | likely susceptible | | 1 | |
| R155G | | | | | | | |
| R155M | | | | | | | |
| R155T | | | | | | | |
| R155W | | | | | | | |
| A156G | | 3x | | likely susceptible | | 1 | |
| A156P | | | | | | | |
| A156S | | 0.7x | | likely susceptible | | 1 | |
| A156T | | | | | | | |
| A156V | | | | | | | |
| V158I | | | | | | | |
| S166A | | | | | | | |
| A166T | | | | | | | |
| A166S | | | | | | | |
| A166Y | | | | | | | |
| Q168A | | 3x | | likely susceptible | | 1 | |
| Q168E | | 0.06x | | likely susceptible | | 1 | |
| Q168F | | | | | | | |
| Q168G | | | | | | | |
| Q168H | | 2x | | likely susceptible | | 1 | |
| Q168I | | | | | | | |
| Q168K | | | | | | | |
| Q168L | | | | | | | |
| Q168N | | 0.2x | | likely susceptible | | 1 | |
| Q168R | | January 1, 1970 | | | | | |
| Q168T | | | | | | | |
| Q168V | | 5x | | resistance possible | | 1 | |
| Q168Y | | | | | | | |
| V170I | | | | | | | |
| V170L | | | | | | | |
| V170M | | | | | | | |
| L175M | | | | | | | |
| Q178R | | | | | | | |
| D186L | | | | | | | |
| D186R | | | | | | | |
| A294V | | | | | | | |
| I366V | | | | | | | |
| K26R+Q168R | | | | | | | |
| V36M+R155K | | | | | | | |
| Q41R+A156T | | | | | | | |
| Q41R+Q168R | | | | | | | |
| Q41R+V170I | | | | | | | |
| Q41R+V55I | | | | | | | |
| Q41T+V170I | | | | | | | |
| T54S+V170I | | | | | | | |
| T54A+V55A | | | | | | | |
| T54S+V55I | | | | | | | |
| V55I+V170I | | | | | | | |
| Y56H+A156G | | | | | | | |
| Y56H+S166A | | | | | | | |
| Y56H+S166T | | | | | | | |
| Y56H+Q168K | | | | | | | |
| Y56H+Q168L | | | | | | | |
| Y56H+Q168R | | | | | | | |
| Y56H+Q168A | | | | | | | |
| Y56H+Q168V | | | | | | | |
| Q80R+ A 166T | | | | | | | |
| Q80R+V170I | | | | | | | |
| C134R+A156T | | | | | | | |
| R155K+A156T | | | | | | | |
| S166A+Q168K | | | | | | | |
| S166A+Q168L | | | | | | | |
| S166A+Q168R | | | | | | | |
| Q168H+A156V | | | | | | | |
| Y56H+S155A+Q168K | | | | | | | |
| Y56H+S155A+Q168L | | | | | | | |
| Y56H+S155A+Q168R | | | | | | | |
| 1. Jensen et al. 2015. AAC 59(12):7426-36 |
Voxilaprevir
| Mutation | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Replication Capacity (%WT) | Comments | SVR with RAV |
| WT (3a_S52) | 6.35 (SD 3.27) | 1x | likely susceptible | | 3 | 100 (4) | mean of 34 clinical isolates, 13xFC vs. GT1a | |
| K26R | | | likely susceptible | | 3 | | | |
| L36W | unfit | | | | 3 | | | |
| Q41H | | | | | | | | |
| Q41K | | 7.3 | resistance likely | Yes | 4,3 | 404 (4) | clinical TE RAV 2% (4) | |
| Q41L | unfit | | | | 3 | | | |
| Q41R | | 5.8x | resistance possible | | 4,3 | 656 (4) | | |
| F43L | unfit | | | | 3 | | | |
| F43S | unfit | | | | 3 | | | |
| F43Y | | | | | 4 | | Clinical VF RAS, 1% (4) | |
| T47I | | 1.1x | likely susceptible | | 4 | | | |
| T54A | | | likely susceptible | | 3 | | | |
| T54S | unfit | | | | 3 | | | |
| V55A | unfit | | resistance possible | Yes | 2,3,4 | | Clincial TE RAS 2.9% (2,4) | |
| V55I | unfit | | | | 3 | | | |
| Y56H | unfit | | | | 3 | | | |
| Y56N | | | | | | | | |
| Q80R | | | likely susceptible | | 3 | | | |
| Q80K | | 2.5x - 20x | resistance likely | Yes | 3,4 | | clinical VF RAV (4) | |
| V107I | | | | | | | | |
| D110N | | 2.2x | likely susceptible | | 4 | | | |
| S122A | | | likely susceptible | | 3 | | | |
| S122C | | | likely susceptible | | 3 | | | |
| S122F | | | likely susceptible | | 3 | | | |
| S122P | unfit | | | | 3 | | | |
| S122R | | | | | | | | |
| S122T | | | likely susceptible | | 3 | | | |
| S122Y | | | likely susceptible | | 3 | | | |
| L132V | | | | | | | | |
| L132I | | | | | | | | |
| C134R | | 1.6x | likely susceptible | | 4 | | | |
| R155C | | | | | | | | |
| R155K | | 0.6x | likely susceptible | | 4,3 | | | |
| R155G | unfit | | | | 3,4 | | Clinical TE RAV 1% (4) | |
| R155M | | | | | 2,4 | | Clincial TE RAS 1.4% (2,4) | |
| R155T | | | | | | | | |
| R155W | unfit | | | | 3 | | | |
| A156G | | | | | 1 | | VOX RAS (1) | |
| A156P | unfit | | | | 3 | | | |
| A156S | | | | | 1 | | >2.5x FC | |
| A156T | | 100x | resistance likely | | 4,2,3 | 23.2 (4) | 100-381x | |
| A156V | | 140x | resistance likely | | 4,2,3 | 5.9 (4) | 140x - >1334x | |
| V158I | | | | | | | | |
| S166A | | | | | | | | |
| A166T | | | | | | | | |
| A166S | | 0.9x | likely susceptible | | 4,3 | | | |
| A166Y | | | | | | | | |
| Q168A | | | | | | | | |
| Q168E | | | | | | | | |
| Q168F | | | | | | | | |
| Q168G | | | | | | | | |
| Q168H | | 1.0x | likely susceptible | | 4,3 | | | |
| Q168I | | | | | | | | |
| Q168K | | | likely susceptible | | 3 | | | |
| Q168L | | | | | | | | |
| Q168N | | | | | | | | |
| Q168R | | 9.4x | resistance possible | | 3,4 | | clincial VF RAS, 1% (4) | |
| Q168T | | | | | | | | |
| Q168V | | | | | | | | |
| Q168Y | | | | | | | | |
| V170I | | 1x | likely susceptible | | 4,3 | | | |
| V170L | | | | | | | | |
| V170M | unfit | | | | 3 | | | |
| L175M | | 2.5x - 20x | resistance possible | | 3 | | | |
| Q178R | | | | | | | | |
| D186L | | | | | | | | |
| D186R | | | | | | | | |
| A294V | | | resistance possible | Yes | 4 | | clinical TE RAV (4) | |
| I366V | | | | | | | | |
| K26R+Q168R | | | likely susceptible | | 3 | | | |
| V36M+R155K | | | | | | | | |
| Q41R+A156T | | 452x | resistance likely | | 4 | | | |
| Q41R+Q168R | | 60x | resistance likely | | 4 | | | |
| Q41R+V170I | | 2.5x - 20x | resistance possible | | 3 | | | |
| Q41R+V55I | | 2.5x - 20x | resistance possible | | | | | |
| Q41T+V170I | | | likely susceptible | | 3 | | | |
| T54S+V170I | unfit | | | | 3 | | | |
| T54A+V55A | unfit | | | | 3 | | | |
| T54S+V55I | unfit | | | | 3 | | | |
| V55I+V170I | | | likely susceptible | | 3 | | | |
| Y56H+A156G | | | | | | | | |
| Y56H+S166A | | | | | | | | |
| Y56H+S166T | | | | | | | | |
| Y56H+Q168K | | | | | | | | |
| Y56H+Q168L | | | | | | | | |
| Y56H+Q168R | | >100x | resistance likely | | 3 | | | |
| Y56H+Q168A | | | | | | | | |
| Y56H+Q168V | | | | | | | | |
| Q80R+ A 166T | | | | | | | | |
| Q80R+V170I | | | likely susceptible | | 3 | | | |
| C134R+A156T | | 149x | resistance likely | | 4 | | | |
| R155K+A156T | | 172x | resistance likely | | 4 | | | |
| S166A+Q168K | | | | | | | | |
| S166A+Q168L | | | | | | | | |
| S166A+Q168R | | | | | | | | |
| Q168H+A156V | | 990x | resistance likely | | 4 | | | |
| Y56H+S155A+Q168K | | | | | | | | |
| Y56H+S155A+Q168L | | | | | | | | |
| Y56H+S155A+Q168R | | | | | | | | |
| 1. Sarrazin C, et al. 2017. Gastroenterology 152: S1062 |
| 2. Vosevi US Product Label 2017 |
| 3. Dvory-Sobol H et al 2017 AASLD. http://www.natap.org/2017/AASLD/AASLD_29.htm |
| 4. FDA Vosevi Microbiology Reviews 209195Orig1s000MicroR |
